Scarica l'app Stockscreener
7.65
0.52%
-0.04
Dopo l'orario di chiusura:
7.55
-0.10
-1.31%
Precedente Chiudi:
$7.69
Aprire:
$7.89
Volume 24 ore:
1.38M
Relative Volume:
2.04
Capitalizzazione di mercato:
$570.03M
Reddito:
-
Utile/perdita netta:
$-27.03M
Rapporto P/E:
-13.66
EPS:
-0.56
Flusso di cassa netto:
$-23.97M
1 W Prestazione:
+5.52%
1M Prestazione:
+33.28%
6M Prestazione:
+136.84%
1 anno Prestazione:
+4.08%
Intervallo 1D:
$7.35
$7.98
Intervallo di 1 settimana:
$6.78
$7.98
Portata 52W:
$2.54
$10.00
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Nome
Corvus Pharmaceuticals Inc
Settore
Industria
Telefono
(650) 900-4520
Indirizzo
863 MITTEN ROAD, BURLINGAME, CA
Confronta CRVS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
7.65 | 524.58M | 0 | -27.03M | -23.97M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-02 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-18 | Iniziato | Oppenheimer | Outperform |
| 2021-12-01 | Ripresa | Jefferies | Buy |
| 2021-05-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-02-10 | Downgrade | Mizuho | Buy → Neutral |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-05-29 | Iniziato | ROTH Capital | Buy |
| 2017-08-24 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | Iniziato | Credit Suisse | Outperform |
| 2016-04-18 | Iniziato | Guggenheim | Buy |
Mostra tutto
Corvus Pharmaceuticals Inc Borsa (CRVS) Ultime notizie
Key resistance and support levels for Corvus Pharmaceuticals Inc.Bull Run & Fast Exit/Entry Strategy Plans - newser.com
Corvus Pharmaceuticals targets expanded soquelitinib trials with Q4 2025 results expected - MSN
Will Corvus Pharmaceuticals Inc. stock go up soonWeekly Profit Summary & Verified Swing Trading Watchlist - newser.com
What technical models suggest about Corvus Pharmaceuticals Inc.’s comebackQuarterly Trade Summary & Weekly Sector Rotation Insights - newser.com
Should you hold or exit Corvus Pharmaceuticals Inc. nowPortfolio Update Report & Daily Profit Focused Stock Screening - newser.com
Using RSI to spot recovery in Corvus Pharmaceuticals Inc.July 2025 News Drivers & Entry and Exit Point Strategies - newser.com
Barclays Initiates Corvus Pharmaceuticals at Overweight With $16 Price Target - MarketScreener
Barclays Initiates Coverage on CRVS with Overweight Rating | CRV - GuruFocus
Barclays initiates Corvus Pharmaceuticals stock with Overweight rating - Investing.com
Barclays initiates Corvus Pharmaceuticals stock with Overweight rating By Investing.com - Investing.com Nigeria
Corvus Pharmaceuticals Inc.’s volatility index tracking explainedShort Setup & Safe Entry Momentum Stock Tips - newser.com
What analysts say about Corvus Pharmaceuticals Inc stockInsider Trading Activity & Free Lightning Fast Capital Gains - earlytimes.in
Weiss Ratings Reaffirms "Sell (D-)" Rating for Corvus Pharmaceuticals (NASDAQ:CRVS) - MarketBeat
Detecting support and resistance levels for Corvus Pharmaceuticals Inc.July 2025 Momentum & Verified Momentum Watchlists - newser.com
Empirical Financial Services LLC d.b.a. Empirical Wealth Management Invests $672,000 in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
Has Corvus Pharmaceuticals Inc. formed a bullish divergenceJuly 2025 Reactions & Breakout Confirmation Trade Signals - newser.com
Published on: 2025-10-03 06:35:03 - newser.com
Measuring Corvus Pharmaceuticals Inc.’s beta against major indicesEarnings Miss & Community Verified Trade Signals - newser.com
Chart based exit strategy for Corvus Pharmaceuticals Inc.July 2025 Macro Moves & Advanced Technical Signal Analysis - newser.com
Candlestick signals on Corvus Pharmaceuticals Inc. stock todayWall Street Watch & Daily Stock Trend Watchlist - newser.com
Corvus Pharmaceuticals appoints David Moore to board of directors - Investing.com
Corvus Pharmaceuticals Appoints David Moore To Board Of Directors - TradingView
Novo Nordisk EVP David Moore Joins Corvus Board to Advance ITK Inhibitor Platform and Commercial Strategy - Stock Titan
Published on: 2025-10-01 07:08:07 - newser.com
What drives Corvus Pharmaceuticals Inc stock priceStock Rotation Strategies & Low Risk Capital Appreciation - earlytimes.in
Is Corvus Pharmaceuticals Inc a good long term investmentRisk-Reward Ratio Analysis & Tap Into the Fastest-Growing Companies - Early Times
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 6.1%Should You Buy? - MarketBeat
Are Investors Undervaluing Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) By 37%? - 富途牛牛
While institutions invested in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) benefited from last week's 12% gain, individual investors stood to gain the most - simplywall.st
Is Corvus Pharmaceuticals Inc. trending in predictive chart modelsMarket Growth Report & Growth Oriented Trade Recommendations - newser.com
What candlestick patterns are forming on Corvus Pharmaceuticals Inc.Weekly Profit Report & Free Daily Entry Point Trade Alerts - newser.com
Is Corvus Pharmaceuticals Inc. forming a reversal patternMarket Trend Report & Reliable Intraday Trade Plans - newser.com
How to integrate Corvus Pharmaceuticals Inc. into portfolio analysis toolsJuly 2025 Short Interest & Weekly Breakout Opportunity Watchlist - newser.com
Corvus Pharmaceuticals Inc Azioni (CRVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Corvus Pharmaceuticals Inc Azioni (CRVS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Thompson Peter A. | Director |
Jun 27 '25 |
Sale |
4.16 |
1,176,332 |
4,891,894 |
7,165,006 |
| Jones William Benton | See Remarks |
Jun 04 '25 |
Option Exercise |
3.50 |
19,357 |
67,750 |
173,130 |
| MILLER RICHARD A MD | President and CEO |
May 07 '25 |
Option Exercise |
3.50 |
559,073 |
1,956,756 |
1,136,707 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):